Browse the evidence

Weekly subcutaneous semaglutide (2.4 mg) significantly improves functional capacity and reduces heart failure hospitalizations in patients with heart failure with preserved ejection fraction (HFpEF) and obesity.

If you have heart failure with preserved ejection fraction (HFpEF) and obesity, ask your doctor about weekly semaglutide injections (2.4 mg). This treatment has been shown to significantly improve your ability to perform daily activities, reduce your body weight, and lower your risk of being hospitalized for heart failure.

GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide) cause significant loss of lean muscle mass (up to 40% of total weight loss), which contributes to reduced resting energy expenditure and increased risk of sarcopenia and weight regain.

If you are taking GLP-1 drugs, expect to lose some muscle along with fat. To protect your metabolism and strength, you must prioritize resistance training and adequate protein intake during your weight loss journey.

The 'borderline stage' of obesity (BMI 28-31.9 kg/m²) is a critical transitional phase characterized by elevated triglycerides, insulin resistance, and low-grade chronic inflammation, representing a vital window for early intervention to prevent clinical obesity.

If your BMI is between 28 and 31.9, do not assume you are safe. Look for metabolic red flags: high triglycerides, insulin resistance, or low-grade inflammation. This is your window to intervene with lifestyle changes (diet, activity) before clinical obesity and its complications set in.

Discontinuation of semaglutide or tirzepatide after 3-12 months of treatment results in negligible average weight change (mean +0.5% for obesity indication, -1.3% for T2D) over the subsequent year, driven by high rates of medication reinitiation (19.6%) or switching to alternative treatments (35.2%).

If you stop semaglutide or tirzepatide, do not assume you will regain all your weight. In clinical practice, most patients either restart the medication or switch to another treatment, which keeps average weight change very small (near zero) over the next year. However, individual results vary widely, so you must actively engage with your healthcare provider to select a replacement strategy (medication or lifestyle) immediately upon discontinuation to avoid regain.

Tirzepatide (a dual GIP/GLP-1 agonist) is better tolerated regarding GI side effects compared to semaglutide (a GLP-1 agonist), likely due to GIP receptor activation having anti-emetic properties.

If you struggle with stomach issues on Semaglutide (Ozempic/Wegovy), ask your doctor about Tirzepatide (Mounjaro/Zepbound). Clinical trials show it causes fewer GI side effects and fewer people stop taking it, possibly because of how it interacts with GIP receptors in the gut.

GLP-1 receptor agonists (GLP-1RAs) significantly reduce body weight, BMI, and waist circumference in patients with psychiatric disorders and obesity, with efficacy comparable to or slightly lower than that observed in non-psychiatric populations.

If you have a psychiatric condition and are overweight, GLP-1 medications (like semaglutide or liraglutide) are a proven, effective option for losing weight, even if you take other psychiatric meds. You will likely lose about 5 kg (11 lbs) on average, which is less than in people without mental health conditions, but still significant. Side effects like nausea are common but usually mild and don't cause most people to stop treatment. Discuss this with your doctor as a priority for metabolic health.

Administering semaglutide to US adults with type 2 diabetes who meet SUSTAIN-6 trial eligibility criteria prevents approximately 75,681 primary composite cardiovascular events annually.

If you have Type 2 Diabetes and meet specific risk criteria (age over 50 with heart/kidney issues, or over 60 with additional risk factors), asking your doctor about semaglutide could potentially prevent tens of thousands of major heart events in your demographic group annually. The medication is a weekly injection that has been shown to significantly lower the risk of heart attack, stroke, and cardiovascular death in clinical trials.

Beta-3 adrenergic receptor agonists (e.g., mirabegron) increase brown adipose tissue activation, metabolic rate, and reduce blood glucose, but are limited by adverse cardiovascular effects.

Mirabegron increases brown fat and metabolism but causes high blood pressure and heart rate. It is not recommended for weight loss due to these cardiovascular risks.

GLP-1 receptor agonists (e.g., liraglutide, semaglutide) induce a weight loss plateau over time, suggesting that appetite suppression alone is insufficient for sustained weight management and highlighting the need for complementary thermogenic strategies.

If you are on a GLP-1 medication like semaglutide or liraglutide and your weight loss has stalled after the first year, this is a common physiological plateau, not a failure. The medication's appetite-suppressing effect has maxed out. To continue losing weight, you may need to add strategies that increase energy expenditure, such as exercise-induced thermogenesis or potentially future thermogenic medications, rather than just relying on the drug alone.

GLP-1 receptor agonists (specifically liraglutide, semaglutide, and tirzepatide) are primarily utilized in clinical practice for obesity treatment rather than type 2 diabetes, with obesity being the dominant indication across these agents.

If you are using GLP-1 medications like Ozempic, Wegovy, or Mounjaro, you are part of a large group using them primarily for weight management, not just blood sugar control. If you dislike injections, ask about oral semaglutide. Be aware that newer drugs like Tirzepatide may be expensive and not covered by insurance, which can lead to stopping treatment early.

Abnormal adiposity is the dominant causal driver of cardiometabolic disease, and targeting it as the primary intervention simplifies management and reduces the need for concurrent pharmacotherapy for downstream drivers like hypertension and dyslipidemia.

Focus on weight loss as the primary treatment for high blood pressure, high blood sugar, and high cholesterol. Instead of taking multiple medications for each issue, prioritize lifestyle changes or weight-loss medications to reduce body fat, as this addresses the root cause that drives all other metabolic risks.

Glucagon receptor agonism (GCGRA), particularly in triagonists like retatrutide, increases energy expenditure and enhances weight loss efficacy compared to GLP-1/GIP agonists alone, though it carries risks of adverse events like tachycardia.

Triagonist medications (combining GLP-1, GIP, and Glucagon effects) can achieve higher weight loss (up to 24%) than current GLP-1 drugs by actively increasing how many calories you burn, not just by reducing appetite. While these drugs can cause side effects like rapid heart rate, doctors can manage this by starting with very low doses and increasing them slowly. This approach offers a more sustainable path to weight loss by counteracting the body's tendency to slow down metabolism.

Metabolic surgery (specifically Roux-en-Y Gastric Bypass and Sleeve Gastrectomy) yields significantly higher diabetes remission rates compared to intensive lifestyle interventions or medical therapy alone.

For eligible patients (BMI >= 35, or >= 27 with comorbidities), metabolic surgery (RYGB or Sleeve Gastrectomy) offers the highest chance of type 2 diabetes remission, significantly outperforming lifestyle changes or medication alone. While upfront costs and surgical risks exist, laparoscopic techniques have made it safer, and it reduces long-term healthcare costs by resolving other obesity-related conditions. Early intervention (shorter diabetes duration) improves success rates.

Thyroid dysfunction and structural changes caused by overnutrition are largely reversible through weight loss and return to a normal diet.

If you have obesity-related thyroid issues, know that they are likely reversible. Losing weight through diet and lifestyle changes can restore normal thyroid function and hormone levels.

Tirzepatide demonstrates high clinical efficacy but has a higher Incremental Cost-Effectiveness Ratio (ICER), making its cost-effectiveness context-dependent.

Tirzepatide is a highly effective once-weekly peptide for weight loss, but its higher cost-effectiveness ratio means it may not be the most economical choice in all healthcare settings compared to Semaglutide.

Phentermine-topiramate (Qysmia) offers acceptable cost-effectiveness, particularly in low-resource settings, making it a practical alternative to more expensive drugs.

For patients in low-resource settings, Phentermine-topiramate (Qysmia) is a cost-effective and practical alternative to more expensive obesity medications.

Tirzepatide improves cardiovascular outcomes in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, reducing heart failure hospitalizations and improving quality of life.

For patients with obesity and heart failure with preserved ejection fraction (HFpEF), tirzepatide (15 mg weekly) has been shown to significantly reduce the risk of heart failure hospitalizations and cardiovascular death. It also improves heart structure and quality of life. This makes it a valuable option for this specific population, in addition to its benefits for diabetes and weight loss.

Tirzepatide is the first pharmacologic therapy approved for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, significantly reducing the Apnea-Hypopnea Index (AHI).

Tirzepatide (Zepbound) is now approved for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. It significantly reduces the number of breathing interruptions per hour (AHI) by 50-60%. This may lead to less daytime sleepiness and potentially reduced reliance on CPAP machines, though long-term data is still emerging.

Multidisciplinary therapy reduces inflammatory biomarkers (CRP, IL-6, TNF-alpha) and improves the leptin/adiponectin ratio in adults with obesity.

Reducing inflammation is a key benefit of weight loss therapy. By losing weight through a multidisciplinary approach, you can lower levels of inflammatory markers like CRP and IL-6, and improve the balance of hormones like leptin and adiponectin, which protects against cardiovascular disease and other complications.

Pharmacological interventions, specifically GLP-1 receptor agonists and SGLT2 inhibitors, reduce epicardial adipose tissue (EAT) volume and improve cardiovascular outcomes, often independent of weight loss.

If you have T2DM, obesity, or heart failure, ask your doctor about GLP-1 agonists or SGLT2 inhibitors. These drugs can reduce the fat around your heart and improve your heart's function, sometimes even without significant weight loss.

In patients with Type 2 Diabetes, GLP-1RA use is strongly associated with prior use of insulin and multiple oral antidiabetic agents, indicating their role as intensification therapies for poorly controlled diabetes.

If you have Type 2 Diabetes and are already taking insulin or multiple oral medications, your provider is likely to prescribe a GLP-1RA as an intensification therapy. This is a standard and effective approach for managing blood sugar when other treatments are insufficient.

GLP-1-based therapies, particularly dual GLP-1/GIP agonists like tirzepatide, produce large, clinically meaningful reductions in AHI and cardiometabolic risk in obesity-associated OSA.

If you have obesity-related sleep apnea, ask your doctor about GLP-1/GIP agonists like tirzepatide. These medications can significantly reduce your apnea severity by reducing weight and metabolic load, offering a systemic treatment option.

GLP-1 and GIP/GLP-1 agonists reduce systemic inflammation (hsCRP, IL-6) and improve metabolic parameters (HbA1c, blood pressure, lipids) in obese patients, contributing to overall cardiovascular risk reduction.

If you are obese, ask your doctor about GLP-1 agonists. They can significantly improve your blood pressure, blood sugar, and inflammation levels, reducing your overall risk of heart disease and stroke.

GLP1R gene polymorphisms (specifically rs10305420 and rs6923761) significantly predict differential weight loss responses to GLP-1 receptor agonists like liraglutide, with certain variants linked to poor anti-obesity response.

If you are struggling to lose weight on GLP-1 medications like liraglutide despite strict adherence, ask your doctor about pharmacogenetic testing for GLP1R variants. Your genetic makeup may dictate whether this specific drug is the right fit for you, helping you avoid ineffective treatments and switch to alternatives sooner.